Events

Paediatric MS: What we know and what we still need to learn

5692 3201 Samyuktha Pillai, PhD

The landscape of paediatric multiple sclerosis (MS) is rapidly evolving. In her presentation titled ‘Pediatric MS – Current treatment strategies and future directions’ at the MS State of the Art…

read more

Multiple sclerosis management in the elderly

5692 3201 Samyuktha Pillai, PhD

The life expectancy in multiple sclerosis (MS) continues to increase and is now comparable to that of the general population.1 This increase comes with the challenge of learning how to…

read more

Preliminary results from stem cell transplantation as an MS therapy in Switzerland

5692 3201 Samyuktha Pillai, PhD

Autologous hematopoietic stem cell transplantation (aHSCT) has been used in the treatment of multiple sclerosis (MS) since 1995 and was approved in Switzerland in June 2018. In their presentation ‘Stem…

read more

MS 2022: Upcoming therapies, and their pros and cons

5692 3201 Samyuktha Pillai, PhD

The repertoire of available multiple sclerosis (MS) disease modifying therapies (DMTs) is constantly growing. In recent years, there have been several new DMTs that have entered the market. In his…

read more

Getting the complete clinical picture: A closer look at smouldering MS

6641 3734 Howard Donohue, PhD

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS, but also in the secondary…

read more

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

6641 3734 Howard Donohue, PhD

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus, natalizumab is associated with a…

read more

Aquaporin-4-positive neuromyelitis optica spectrum disorder: A favourable long-term benefit-risk profile of eculizumab treatment

6641 3734 Howard Donohue, PhD

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease that typically affects the optic nerves and spinal cord.1,2 At least two-thirds of cases are associated with aquaporin-4 (AQP4) antibodies…

read more

Integrative medicine for multiple sclerosis: Outcomes from the Inspire MS program

5692 3201 Howard Donohue, PhD

A growing body of evidence suggests that integrative medicine (IM) modalities can enhance the comprehensive care of patients with multiple sclerosis (MS). Thirty to eighty percent of patients with MS…

read more

To stay or to switch? Assessing long-term treatment outcomes and impact of treatment on patients’ quality of life

6641 3734 Howard Donohue, PhD

The main concerns of patients, regarding their treatment, include disease control and safety, but they also want to make sure that their day-to-day life remains as close to normal as…

read more
Brainwork is supported by unrestricted grants from: